Replimune Announces Appointment of Emily Hill as Chief Financial Officer Woburn, MA

Replimune Announces Appointment of Emily Hill

as Chief Financial Officer

Woburn, MA, September 19, 2023

- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio

of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently

CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences

industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical

"Emily brings a wealth of financial planning and strategy experience

to Replimune that will be impactful as we look to transition to a commercial stage company," said Philip Astley-Sparke, CEO of Replimune.

"On behalf of the leadership team at Replimune, I would like to welcome Emily to the Company and we all look forward to working

with her to realize our ambition of building a major skin cancer franchise."

"Replimune is on the cusp of major value inflection points with

data from two potentially registrational trials anticipated in the coming months," commented Ms. Hill. "I'm looking forward

to applying my expertise and experience to help Replimune continue its growth and make the transition from a clinical to commercial stage

Prior to joining Replimune, Emily held numerous positions at PTC Therapeutics

where she headed up Investor Relations before becoming the Company's Chief Financial Officer. Emily was heavily involved in PTC's

evolution from a development stage company to a five product company generating revenues approaching $1billion. Prior to PTC Therapeutics,

Emily was Director of Investor Relations at Warner Chilcott where she was responsible for leading the function until the Company was acquired

by Actavis for approximately $8.5 billion. Additionally, Ms. Hill was Senior Manager of Investor Relations at Genzyme Corporation.

Prior to Genzyme, Emily was a Biotech Equity Research Associate at Summer Street Partners. Ms. Hill has an MBA with a concentration

in Finance from Fordham University, a Masters of Science in Pharmacology from Tufts University School of Biomedical Research, and a BA

from Hamilton College.

Replimune Group, Inc., headquartered

in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies.

Replimune's proprietary RPx platform is based on a potent HSV-1 backbone with added payloads intended to maximize immunogenic cell

death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to provide a unique dual local and systemic

mechanism of action consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens

and altering of the tumor microenvironment to ignite a strong and durable systemic response. This MOA is expected to be synergistic with

most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility

to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Forward Looking Statements

This press release contains forward looking statements within the meaning

of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,

including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes

to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient

enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as "could,"

"expects," "intends," "may," "plans," "potential," "should," "will,"

"would," or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees

of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could

cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related

to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing

of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which

we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including

the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time

in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange

Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking

statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking

Westwicke, an ICR Company